Search

Your search keyword '"Ehmer, Ursula"' showing total 257 results

Search Constraints

Start Over You searched for: Author "Ehmer, Ursula" Remove constraint Author: "Ehmer, Ursula"
Sorry, I don't understand your search. ×
257 results on '"Ehmer, Ursula"'

Search Results

3. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

5. Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study

8. CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver

9. PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.

11. PARP-1 selectively impairsKRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma

12. THU-457 Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitorbased therapy-first results from an international multicenter registry

15. Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC.

16. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

17. Community-driven development of a modified progression-free survival ratio for precision oncology

18. Organ Size Control Is Dominant over Rb Family Inactivation to Restrict Proliferation In Vivo

19. Human hepatic organoids for the analysis of human genetic diseases

20. Frequent Follow-Up of Delisted Liver Transplant Candidates Is Necessary: An Observational Study about Characteristics and Outcomes of Delisted Liver Transplant Candidates

21. Response to the letter re: Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: A nationwide, population-based study

22. Comparison of histological tumour response in patients with hepatocellular carcinoma after transarterial chemoembolization, stereotactic body radiation, or combined therapy

24. Risk of bleeding and thromboembolic events with atezolizumab/bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter, retrospective study

25. Inhibition of SARS-CoV-2 infection by vaccine-induced antibodies and small-interfering RNAs

26. Frequent Follow-Up of Delisted Liver Transplant Candidates Is Necessary: An Observational Study about Characteristics and Outcomes of Delisted Liver Transplant Candidates

30. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice

32. Intestinal myofibroblasts regulate intestinal epithelial cell plasticity via YAP/TAZ

34. Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature.

37. The spatial distribution and detailed composition of infiltrating immune cells define autoimmune- and checkpoint-therapy associated hepatitis

38. Expression of human endogenous retrovirus type K HML2 in hepatitis C patients treated with direct acting antiviral therapy

39. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol

40. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial

41. Expression of human endogenous retrovirus type K HML2 in hepatitis C patients treated with direct acting antiviral therapy

42. A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer

43. IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results.

44. Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis

45. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol

46. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma : The DEMAND trial protocol

47. OS-079-YI Development and validation of the CABLE score to estimate individual prognosis of patients with hepatocellular carcinoma treated with 1L atezolizumab and bevacizumab

48. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial.

49. Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study

50. Relevance of MEK/ERK signaling in biliary differentiation in murine liver cancer

Catalog

Books, media, physical & digital resources